Table 2.

NRI in the NPHS-II and EAS studies using Framingham-based models with and without CRP: (A) using four 10-year CHD risk categories and (B) using categories based on a threshold for intervention of a 10-year CHD risk of >15%

Panel A
Predicted 10-year CHD risk
Framingham variables plus CRP
	No. of individuals				Reclassified
Framingham variables	<5%	5–10%	10–15%	>15%	Increased risk	Decreased risk	Net correctly reclassified
NPHS-II study
Individuals without CHD events during follow-up (n = 2253)
0–<5%	890	181	0	0	331	325	−0.3%
5–10%	242	604	115	4
10–15%	2	63	73	31
≥15%	0	2	16	30
Individuals with CHD events during follow-up (n = 159)
0–<5%	38	10	0	0	37	23	8.8%
5–10%	12	40	17	2
10–15%	0	10	12	8
≥15%	0	0	1	9
NRI (95% CI)							8.5% (−1.3, 18.3)
Edinburgh Artery Study
Individuals without CHD events during follow-up (n = 777)
0–<5%	247	23	0	0	83	124	5.3%
5–10%	59	219	32	2
10–15%	0	46	56	26
≥15%	0	2	17	48
Individuals with CHD events during follow-up (n = 142)
0–<5%	18	5	0	0	26	21	3.5%
5–10%	9	29	9	0
10–15%	0	6	27	12
≥15%	0	1	5	21
NRI (95%CI)							8.8% (−1.3 to 18.9)

Panel B
Predicted 10-year CHD risk
Framingham variables plus CRP
	No. of individuals		Reclassified
Framingham variables	0–15%	≥15%	Increased risk	Decreased risk	Net correctly reclassified
NPHS-II study
Individuals without CHD events during follow-up (n = 2253)
0–15%	2170	35	35	18	−0.8%
≥15%	18	30
Individuals with CHD events during follow-up (n = 159)
0–15%	139	10	10	1	5.7%
≥15%	1	9
NRI (95%CI)					4.9% (0.8, 9.0)
Edinburgh Artery Study
Individuals without CHD events during follow-up (n = 777)
0–15%	682	28	28	19	−1.2%
≥15%	19	48
Individuals with CHD events during follow-up (n = 142)
0–15%	103	12	12	6	4.2%
≥15%	6	21
NRI (95%CI)					3.0% (−3.0, 9.2)